Here are some "bits and pieces" updates for December. Update on Dr. Faustman's Phase-II Trial of BCG Dr. Faustman's lab has published their Fall 2017 newsletter, which you can read here: http://www.faustmanlab.org/docs/newsletters/DrFaustmanUpdateFall2017.pdf This newsletter includes more information on her research, especially from the 3rd International BCG conference, The BCG Working Group, and the 2nd edition of the BCG and Autoimmunity book she edited. There are three pieces of new news there: The phase-II trial was fully enrolled in Summer of 2017. This is important because we now know when the trial will end. Since this is a five year study, they should finish collecting data in Summer of 2022 and publish before Summer of 2023. They have given BCG to the three untreated patients from their phase-I trial, so they will have data from six people to report in the future. The lab is going to be recruiting for more studies in the future, so would like to hear from anyone who is interested in participating. No details on future trials were provided. Another piece of news is that Dr. Faustman is branching out, and trying to apply BCG treatment to Fibromyalgia. This research is being done in collaboration with EpicGenetics, and they hope to start the trial in early 2018. If anything applicable to the type-1 world comes up in this research, I'll report it. Since Fibromyalgia is not generally considered an autoimmune disease, I'm not sure how much "cross pollination" of results there will be. You can read more about it here: http://www.prohealth.com/library/showarticle.cfm?libid=30644 http://www.businesswire.com/news/home/20170419005324/en/EpicGenetics-Assistance-Leading-Medical-Centers-Expands-Clinical DILfrequency Trial Completed There is a lot of research ongoing on IL-2 which is part of the immune system. About 18 months ago, I summarized all this research here: http://cureresearch4type1diabetes.blogspot.com/2016/05/general-update-on-il-2-research.html with an update here: http://cureresearch4type1diabetes.blogspot.com/2017/01/possible-cures-for-type-1-in-news.html One of those clinical trials was called "DILfrequency" and that trial has finished, and the results published. The purpose of that trial was to develop the best dosing method of IL-2 which could then be used in future trials. ("Best" in this case, meant a stable and known change in the immune system, which the researchers wanted.) It was successful in terms of telling the researchers what they wanted to know to prepare for future clinical studies. There are several IL-2 research projects either ongoing or planned to start (including by this group), so I think we'll get a stronger signal in the next few years. Journal Article: https://www.biorxiv.org/content/early/2017/11/28/223958 Clinical Trial Record: https://clinicaltrials.gov/ct2/show/NCT02265809 Joshua Levy http://cureresearch4type1diabetes.blogspot.com publicjoshualevy at gmail dot com All the views expressed here are those of Joshua Levy, and nothing here is official JDRF or JDCA news, views, policies or opinions. My daughter has type-1 diabetes and participates in clinical trials, which might be discussed here. My blog contains a more complete non-conflict of interest statement. Thanks to everyone who helps with the blog.